Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
26.4M
-
Shares change
-
+203K
-
Total reported value, excl. options
-
$71.8M
-
Value change
-
+$426K
-
Put/Call ratio
-
0.75
-
Number of buys
-
33
-
Number of sells
-
-47
-
Price
-
$2.72
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q3 2022
111 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q3 2022.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.4M shares
of 112M outstanding shares and own 23.51% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.33M shares), MILLENNIUM MANAGEMENT LLC (3.1M shares), Balyasny Asset Management LLC (2.67M shares), BlackRock Inc. (1.47M shares), MARSHALL WACE, LLP (1.34M shares), Laurion Capital Management LP (1.3M shares), Walleye Capital LLC (1.1M shares), RENAISSANCE TECHNOLOGIES LLC (1.05M shares), TWO SIGMA INVESTMENTS, LP (986K shares), and DIMENSIONAL FUND ADVISORS LP (914K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.